Research Study

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
Principal Investigator 
Anthony Traboulsee

Overview

Body Locations and Systems 
Eye Disorders
ClinicalTrials.gov# 
NCT02073279
Status 
Recruiting
Study Start/End 
Jun 1, 2014 to Dec 28, 2017
Locations 
UBC Hospital
Name/Title 
Neila Tong, Study Coordinator
Phone 
604-827-1892
Email Address 
neila.tong@ubc.ca
Purpose of Study 

The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic and immunogenic profiles of SA237 in patients with NMO and NMOSD.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.